Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor ... Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.244 | 28.1755196305 | 0.866 | 1.14 | 0.83 | 1685185 | 0.98136274 | CS |
| 4 | -0.3 | -21.2765957447 | 1.41 | 1.42 | 0.783 | 1285565 | 1.06928437 | CS |
| 12 | -0.91 | -45.0495049505 | 2.02 | 2.3 | 0.783 | 1177499 | 1.5145088 | CS |
| 26 | -1.23 | -52.5641025641 | 2.34 | 3.39 | 0.783 | 1421088 | 2.01119467 | CS |
| 52 | -3.53 | -76.0775862069 | 4.64 | 5.66 | 0.783 | 1267913 | 2.41768239 | CS |
| 156 | -11.91 | -91.4746543779 | 13.02 | 47.2508 | 0.783 | 1328950 | 10.64945649 | CS |
| 260 | -17.54 | -94.0482573727 | 18.65 | 47.2508 | 0.783 | 1169822 | 10.78080277 | CS |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
